Gazeta Lodz - Morning-after pill more effective when taken with painkiller: study

The study, published on Wednesday in The Lancet, was conducted at a reproductive health services centre in the Chinese city between 2018 and 2022, and used a randomised controlled trial of 860 women who requested emergency contraception.

A 1998 trial found that levonorgestrel, one of the world's most popular morning-after pills, was 95 percent effective at preventing pregnancies when taken within 24 hours of unprotected sex.

But the study's authors said taking it alongside piroxicam -- a prescription medicine commonly used to treat arthritic pain and inflammation -- "significantly improved the emergency contraception efficacy".

Out of a group of 418 women who took both levonorgestrel and piroxicam, only one became pregnant, for an overall effectiveness rate of 99.8 percent.

Another group of the same size that took levonorgestrel and a placebo saw seven pregnancies, for an effectiveness rate of 98.3 percent.

Co-investigator Sue Lo, from the Family Planning Association of Hong Kong, told AFP the findings were "really exciting", calling it a "pioneer discovery" that she hoped could be built on by other researchers.

"For the general public, the emergency contraceptives that we have been using (are) really good... We're lucky that we find something to perfect the regimen," she said.

The two test groups showed no significant difference in the rates of side effects such as late periods, the researchers said.

The study was the first to suggest that a "readily available and safe" medication taken together with levonorgestrel can boost its effectiveness, said the study's first author, Raymond Li of the University of Hong Kong.

However, Lo stressed that the findings still needed to be replicated before they could lead to policy change.

"It's a little bit too early to ask women to add (piroxicam) into their regimen at this point," she said.

"Anybody who needs emergency contraception should go to see a doctor... Whether she should add another prescription drug on top of (levonorgestrel), she should discuss with a doctor."

Writing in a separate commentary in The Lancet, Erica Cahill from the Stanford University School of Medicine cautioned that the conclusion "might not apply to all patients".

The study participants were mostly of Asian ethnicity and weighed less than 70 kilograms (154 pounds), said Cahill, who was not involved in the study.

The improved effectiveness "might not be generalisable to patients with higher BMIs".

F.Jablonski--GL